New drugs in early-stage clinical trials for allergic rhinitis

References

• Mims JW. Epidemiology of allergic rhinitis. Int Forum Allergy Rhinol. 2014;4(Suppl 2):S18–20.
   PubMed Web of Science ®Google Scholar
• Compalati E, Ridolo E, Passalacqua G, et al. The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol. 2010;6(3):413–423.
   PubMed Web of Science ®Google Scholar
• Baiardini I, Braido F, Tarantini F, et al. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy. 2008;63(6):660–669.
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124(3):428–433.
   PubMed Web of Science ®Google Scholar
• International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy. 1994;49(19 Suppl):1–34.
   Google Scholar
• Heffler E, Madeira LNG, Ferrando M, et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J Allergy Clin Immunol Pract. 2018;6(3):776–781.
   PubMed Web of Science ®Google Scholar
• Åberg N, Dahl Å, Benson M. A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load. Pediatr Allergy Immunol. 2011;22:594–599.
   PubMed Web of Science ®Google Scholar
• Åberg N, Ospanova ST, Nikitin NP, et al. A nasally applied cellulose powder in seasonal allergic rhinitis in adults with grass pollen allergy: a double-blind, randomized, placebo-controlled, parallel-group study. Int Arch Allergy Immunol. 2014;163(4):313–318.
   PubMed Web of Science ®Google Scholar
• Andersson M, Greiff L, Wollmer P. Effects of a topical microemulsion in house dust mite allergic rhinitis. Basic Clin Pharmacol Toxicol. 2011;108:146–148.
   PubMed Web of Science ®Google Scholar
• Böhm M, Avgitidou G, El Hassan E, et al. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2012 Feb;269(2):495–502.
   PubMed Web of Science ®Google Scholar
• Mahmoodi NS, Reza Okhovat SA, Reza Abthai SH, et al. The comparison of nasaleze and mometasone nasal spray to control the symptoms of allergic rhinitis. Adv Biomed Res. 2018 Feb;16(7):27.
   Google Scholar
• Emberlin JC, Lewis RA. A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Curr Med Res Opin. 2006;22:275–285.
   PubMed Web of Science ®Google Scholar
• Fathololoumi MRDAL, Ramezankhani O, Nouhi S, et al. Comparison of systemic and local corticosteroids on the clinical and laboratory parameters in patients with perennial allergic rhinitis. Res Med. 2010;34:92–97.
   Google Scholar
• De Servi B, Ranzini F, Piqué N. Protective barrier properties of rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017;13:37.
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220.
   PubMed Web of Science ®Google Scholar
• Lee M, Kim S, Kwon OK, et al. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol. 2009;9:418–424.
   PubMed Web of Science ®Google Scholar
• Miraglia Del Giudice M, Maiello N, Capristo C, et al. Resveratrol plus carboxymethyl-β-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Curr Med Res Opin. 2014;30:1931–1935.
   PubMed Web of Science ®Google Scholar
• Lv C, Zhang Y, Shen L. Preliminary clinical effect evaluation of resveratrol in adults with allergic rhinitis. Int Arch Allergy Immunol. 2018;175:231–236.
   PubMed Web of Science ®Google Scholar
• Relja B, Omid N, Wagner N, et al. Ethanol, ethyl and sodium pyruvate decrease the inflammatory responses of human lung epithelial cells via Akt and NF-κB in vitro but have a low impact on hepatocellular cells. Int J Mol Med. 2016 Feb;37(2):517–525.
   PubMed Web of Science ®Google Scholar
• Li LS, Wang RQ, Guan K. Treatment effect of sodium pyruvate nasal spray on allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jan 20;31(2):103–106.
   PubMedGoogle Scholar
• Pozzoli M, Traini D, Young PM, et al. Development of a soluplus budesonide freeze-dried powder for nasal drug delivery. Drug Dev Ind Pharm. 2017 Sep;43(9):1510–1518.
   PubMed Web of Science ®Google Scholar
• Jullaphant T, Nakpeng T, Srichana T. Montelukast nasal spray: formulation development and in vitro evaluation. Pharm Dev Technol. 2018 Sep;27:1–10.
   Google Scholar
• Senturk E, Yildirim YS, Dogan R, et al. Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis. Eur Arch Otorhinolaryngol. 2018;275:117.
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128:1139–50 e4.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA Jr., Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012;129:409–12, 12 e1–e2.
   PubMed Web of Science ®Google Scholar
• Ridolo E, Montagni M, Melli V, et al. Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother. 2014;15:73–83.
   PubMed Web of Science ®Google Scholar
• Dongdong Z, Yu H, Ran S, et al. JNJ7777120, the histamine receptor 4 antagonist, decreases the allergic remodeling and Th2 inflammation in a rat model of allergic rhinitis. Int J Clin Exp Med. 2017;10:8.
   Web of Science ®Google Scholar
• Ratner P, Andrews CP, Hampel FC, et al. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma Clin Immunol. 2017;13:18.
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67:1572–1579.
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Kuna P. Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs. 2017;77:1281–1294.
   PubMed Web of Science ®Google Scholar
• Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2001;108:530–536.
   PubMed Web of Science ®Google Scholar
• Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: the present and the future. Hum Vaccin Immunother. 2012;8:1534–1543.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105:17908–17912.
   PubMed Web of Science ®Google Scholar
• Vadlamudi A, Shaker M. New developments in allergen immunotherapy. Curr Opin Pediatr. 2015;27:649–655.
   PubMed Web of Science ®Google Scholar
• Martínez-Gómez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150:59–65.
   PubMed Web of Science ®Google Scholar
• Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17:10.
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy. 2015;70:707–710.
   PubMed Web of Science ®Google Scholar
• von Moos S, Kündig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011;31:391–406.
   PubMed Web of Science ®Google Scholar
• Rotiroti G, Shamji M, Durham SR, et al. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol. 2012;130:918–24.e1.
   PubMed Web of Science ®Google Scholar
• Slovick A, Douiri A, Muir R, et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. Allergy Clin Immunol. 2017;139:1830–1839.e13.
   Google Scholar
• Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–140.
   PubMed Web of Science ®Google Scholar
• Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007;120:688–695.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Bendiks M, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013;24:427–433.
   PubMed Web of Science ®Google Scholar
• Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:323–329.
   PubMed Web of Science ®Google Scholar
• Eckman JA, Sterba PM, Kelly D, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol. 2010;125:889–895.e7.
   PubMedGoogle Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170:122–131.
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142:171–177.e1.
   PubMed Web of Science ®Google Scholar
• Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297–1305.
   PubMed Web of Science ®Google Scholar
• Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int. 2016 Jul;65(3):243–252.
   PubMed Web of Science ®Google Scholar
• Manka LA, Wechsler ME. New biologics for allergic diseases. Expert Rev Clin Immunol. 2018;14(4):285–296.
   PubMed Web of Science ®Google Scholar
• Heffler E, Bagnasco D, Canonica GW. Strategies to reduce corticosteroid-related adverse events in asthma. Curr Opin Allergy Clin Immunol. 2018. DOI:10.1097/ACI.0000000000000493
   PubMed Web of Science ®Google Scholar